Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer

NCT02093962 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT02093962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02093962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
Lead sponsor
ImmunoGenesis
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2014
Completion date
May 31, 2016
Enrollment
265 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer